)
Edge14 Aug 2026
Deutsche Qualität: The Story of Birkenstock
From an 18th-century German shoemaker to a global footwear brand, how Birkenstock turned an orthopedic insole into the world's most popular sandal.
NeoImmuneTech
NeoImmuneTech (950220) investor relations material
NeoImmuneTech Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary12 Aug, 2026
Executive summary
Focuses on T cell-based immunotherapy R&D, with NT-I7 as the core pipeline and Endari® commercialized in North America.
Achieved first commercial sales of Endari® in the US in May 2026, expanding revenue streams.
Maintains a dual business model: innovative drug development and commercial product sales.
Financial highlights
1H 2026 revenue: $1.15M, up from $66.7K in 2025 and $124.9K in 2024, driven by Endari® sales.
Operating loss for 1H 2026: $(7.08)M, improved from $(17.7)M in 2025 and $(29.4)M in 2024.
Net loss for 1H 2026: $(5.45)M, compared to $(22.4)M in 2025 and $(29.97)M in 2024.
Cash and equivalents at June 2026: $22.8M, down from $27.1M at end-2025.
R&D expenses for 1H 2026: $3.89M (34% of sales), down from $11.6M in 2025 and $20.1M in 2024.
Outlook and guidance
Expects continued revenue growth from Endari® and potential licensing deals for NT-I7.
Strategic focus on advancing NT-I7 clinical trials and expanding commercial partnerships.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from NeoImmuneTech
- No revenue, USD 16M net loss, and strong R&D focus as clinical pipeline advances.950220
Q2 2024 - Q3 2024: High R&D spend, ongoing losses, new orphan drug designations, $12M bond issued.950220Q3 2024
- Net loss narrowed to $30M on $124K revenue, but liquidity and going concern risks persist.950220Q4 2024
- Q1 2025: Ongoing losses, high R&D spend, minimal revenue, and strong reliance on future licensing.950220Q1 2025
- Losses narrowed, equity rose 46%, and first product revenue is expected in 2026.950220Q4 2025
- Operating losses persist as R&D advances; capital raise planned to address liquidity.950220Q2 2025
- Q3 2025: High R&D costs, no product sales, major equity raise, and ongoing clinical progress.950220Q3 2025
- Q1 2026 revenue was $359,672 with a net loss of $5.15 million and high R&D intensity.950220Q1 2026
Next NeoImmuneTech earnings date
Q3 20266 Nov, 2026
NeoImmuneTech
Next NeoImmuneTech earnings date
Q3 20266 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage